![Steven N. Gordon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Steven N. Gordon
Direttore/Membro del Consiglio presso Équilibre BioPharmaceuticals Corp.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Philip Barach | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Steven N. Gordon | M | 56 |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Francois Maisonrouge | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Peter Simon | M | 75 |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
David Freidman | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Christina M. Ramirez | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 6 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Steven N. Gordon
- Contatti personali